Novo Nordisk A/S $NVO Stock: Pekin Hardy Strauss Inc. Raises Position

Pekin Hardy Strauss Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 134.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 164,673 shares of the company’s stock after acquiring an additional 94,513 shares during the quarter. Pekin Hardy Strauss Inc.’s holdings in Novo Nordisk A/S were worth $6,243,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership purchased a new position in Novo Nordisk A/S during the first quarter worth about $287,660,000. State Street Corp raised its holdings in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after acquiring an additional 32,641 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Novo Nordisk A/S by 3.2% in the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Novo Nordisk A/S by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after acquiring an additional 71,684 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after acquiring an additional 213,443 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on NVO shares. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price on the stock. in a research note on Tuesday, September 22nd. Barclays reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S Stock Down 4.5%

NVO opened at $40.29 on Friday. The stock has a market cap of $179.89 billion, a PE ratio of 10.15, a P/E/G ratio of 1.42 and a beta of 0.70. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The business’s fifty day simple moving average is $40.70 and its 200 day simple moving average is $43.96.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 54.22% and a net margin of 33.99%. The firm had revenue of $11.98 billion during the quarter. As a group, research analysts expect that Novo Nordisk A/S will post 3.44 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Third-quarter results beat expectations: adjusted sales were DKK 79.2 billion, obesity sales grew 22%, and adjusted operating profit increased 27%. Novo raised its full-year 2026 outlook, citing demand for its GLP-1 portfolio. Reuters: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: Wegovy pill adoption exceeded management’s expectations and came in ahead of forecasts, bolstering the growth outlook. Novo plans to expand the pill into more than 20 markets by mid-2027. BioPharma Dive: Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
• Positive Sentiment: Novo and Abbott are expanding their diabetes-drug collaboration in Asia, potentially supporting wider regional reach. MarketScreener: Abbott and Novo Nordisk expand collaboration on diabetes drug in Asia
• Neutral Sentiment: The company did not provide 2027 guidance. Management cited factors that could help or hinder next year’s sales, leaving investors without a firm near-term growth target. The Motley Fool: Novo Nordisk Stock Jumped After Earnings — But Its CEO Won’t Give 2027 Guidance
• Negative Sentiment: Despite solid sales, coverage highlights a squeeze on profits, while impairment charges weighed on reported operating profit. Pricing pressure and questions about future margins may be tempering enthusiasm for the outlook. Yahoo Finance: Novo Nordisk Stock Faces Q3 Earnings Profit Squeeze
• Negative Sentiment: CFO Karsten Munk Knudsen is leaving the company. The upcoming handover adds a management transition as investors assess the earnings and outlook. Reuters: Novo Nordisk’s CFO Karsten Munk Knudsen to leave company

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.